title: Endpoints for clinical trials of sarcoidosis.
abstract: Over the past few years an increasing number of prospective controlled sarcoidosis treatment trials have been completed. Unfortunately, these studies utilize different endpoints making comparisons between studies difficult. At the recent World Association of Sarcoidosis and other Granulomatous disease (WASOG) meeting, a session was dedicated to the evaluation of clinical endpoints for various disease manifestations. These included pulmonary, pulmonary hypertension, fatigue, cutaneous, and a classification of clinical disease phenotypes. Based on the available literature and our current understanding of the disease, recommendations for clinical evaluation were proposed for each disease category. For example, it was recommended that pulmonary studies should include changes in the forced vital capacity. Additionally, it was recommended that all trials should incorporate measurement of quality of life.
authors: University of Cincinnati Medical Center, Cincinnati, OH, USA. bob.baughman@uc.edu
authors: R P
authors: RP
authors: Baughman
authors: M
authors: M
authors: Drent
authors: D A
authors: DA
authors: Culver
authors: J C
authors: JC
authors: Grutters
authors: T
authors: T
authors: Handa
authors: M
authors: M
authors: Humbert
authors: M A
authors: MA
authors: Judson
authors: E E
authors: EE
authors: Lower
authors: J
authors: J
authors: Mana
authors: C A
authors: CA
authors: Pereira
authors: A
authors: A
authors: Prasse
authors: R
authors: R
authors: Sulica
authors: D
authors: D
authors: Valyere
authors: V
authors: V
authors: Vucinic
authors: A U
authors: AU
authors: Wells
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods*; D019468:Disease Management; D006801:Humans; D011788:Quality of Life; D012129:Respiratory Function Tests; D017565:Sarcoidosis, Pulmonary / Q000175:diagnosis* / Q000628:therapy*; D012720:Severity of Illness Index